Trial reportGerman medical science : GMS e-journal2010
Probiotic treatment of irritable bowel syndrome in children.
Trial report in German medical science : GMS e-journal, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Efficacy and Safety of the Adjuvant Use of Probiotic Bacillus clausii Strains in Pediatric Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study.Paediatric drugs · 2023Trial
- Trial
- Probiotic formulations and gastro-intestinal diseases in the paediatric population: a narrative review.Annals of medicine and surgery (2012) · 2024Review
- Evaluating the effects of probiotics in pediatrics with recurrent abdominal pain.Clinical and experimental pediatrics · 2020Article
- The relationship between calcium oxalate lithiasis and chronic proinflammatory intestinal dysbiosis pattern: a prospective study.Urolithiasis · 2020Article
- Symbioflor2Microorganisms · 2020Article
- Effects of Live and Heat-InactivatedEuropean journal of microbiology & immunology · 2018Article
- The Management of Paediatric Functional Abdominal Pain Disorders: Latest Evidence.Paediatric drugs · 2018Review
- Insights from 100 Years of Research with ProbioticEuropean journal of microbiology & immunology · 2016Review
- A Review of Research Conducted with ProbioticInternational journal of bacteriology · 2016Review
- Probiotic for irritable bowel syndrome in pediatric patients: a randomized controlled clinical trial.Electronic physician · 2015Article
- Complete Sequence of Probiotic Symbioflor 2 Escherichia coli Strain G3/10 and Draft Sequences of Symbioflor 2 E. coli Strains G1/2, G4/9, G5, G6/7, and G8.Genome announcements · 2015Article
- Irritable bowel syndrome in children: pathogenesis, diagnosis and evidence-based treatment.World journal of gastroenterology · 2014Review
- Article
- Identification and characterization of microcin S, a new antibacterial peptide produced by probiotic Escherichia coli G3/10.PloS one · 2012Article
- Functional abdominal pain in childhood: background studies and recent research trends.Pain research & managementReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledTreatment of functional bowel disorders of irritable bowel-type (IBS) in children remains a difficult task because of a lack of drugs with low adverse event profile. We here report the results of a treatment study in 203 children (66 boys and 137 girls) age 4 to 18 years (mean: 10.5+/-4.5 years) with typical IBS symptoms with abdominal pain and either predominant diarrhea (n=50), constipation (n=56), alternating stool frequency (n=28) or unspecific pain (n=69). The average duration of symptoms prior to therapy was 175 days. Most (95%) patients up to age 11 were treated with a daily dose of 10 drops of Symbioflor 2 (SF2) (SymbioPharm, Herborn) (cells and autolysate of 1.5-4.5x10(7) CFU of bacteria of Escherichia coli type), in the elder children 77% received this dosage, while the remaining received a higher dose up to 30 drops/day. Treatment lasted 43 days on average.
resultsAll patients tolerated the treatment well and without adverse events. The key IBS symptoms (abdominal pain, stool frequency) as well as the other symptoms (bloating, mucous and blood in stool, need for straining at stools, urge to defecate) improved significantly during treatment. Global assessment of therapy by parents and doctors was altogether positive. In summary these data confirm efficacy and tolerability of this probiotic compound in children and adolescents and supplement published data of probiotic IBS therapy in adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.